Marijuana (Cannabis) Use Disorder

Marijuana (Cannabis) Use Disorder is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or .

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

-- The first section of this topic is shown below --

Basics

Description

  • Marijuana use leading to clinically significant impairment or distress, manifested by two or more of the following symptoms within a 12-month period:
    • Consumption of larger amounts over a longer period of time than intended
    • Persistent desire or inability to cut down or control amount used
    • Inordinate amount of time spent in activities is necessary to obtain, use, or recover from use
    • Presence of craving for cannabis
    • Recurrent use resulting in failure to fulfill major role obligations at work, school, or home
    • Continued use despite having persistent or recurrent social or interpersonal problems due to cannabis use
    • Important social, occupational, or recreational activities are given up or reduced
    • Recurrent use in physically hazardous situations
    • Continued use despite knowledge of a persistent physical or psychological problem caused or exacerbated by cannabis
    • Tolerance defined by using increased amounts of cannabis to achieve the desired effect or intoxication or diminished effect with continued use of the same amount
    • Withdrawal occurs following cessation of prolonged use and has at least three behavioral symptoms such as anxiety, restlessness, depression, irritability, insomnia, odd dreams or physical symptoms such as tremors and/or decreased appetite.
  • According to DSM-5, marijuana or cannabis use disorder is defined as being mild, moderate, or severe depending on how many symptoms are present. Mild: 2 to 3; moderate: 4 to 5; severe: 6+ (1)

Epidemiology

  • The WHO ranks the United States first among 17 European and North American countries for the prevalence of marijuana use.
  • It is estimated that 4.5 to 7 million persons in the United States meet criteria for cannabis use disorder (CUD) annually (2).
  • The prevalence of daily cannabis use in the United States has doubled in the past 2 decades.
  • Cannabis use disorder applies to a subset of marijuana users; ~20% of lifetime marijuana users meet criteria for cannabis use disorder; 23% of these individuals meet criteria for severe use.
  • Risk of CUD is estimated to be 1 in 11 (9%) in adults and 1 in 6 (17%) in adolescents (2).
  • Cannabis is the most widely used illicit psychoactive substance in the United States (22.2 million monthly users) (3).
  • Approximately 30% of students have used marijuana by the time of college entry.
  • In the United States, 10% of marijuana users become daily users, 20–30% become weekly users.
  • In the general population of young people, individuals who use high-potency cannabis are more likely to use cannabis regularly, have cannabis-related problems, use other illicit drugs, and have general anxiety disorder.
  • The landscape is changing rapidly. Many states have legalized marijuana in some form. In 1969, only 12% of people approved of legalizing marijuana; by 2019, 67% approved of legalization.

Etiology and Pathophysiology

  • The two most known therapeutically active cannabinoids in marijuana are δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). While CBD has become much more widely available, it remains prohibited by the FDA.
  • THC is the psychoactive component responsible for marijuana’s analgesic, antiemetic, and intoxicating properties.
  • Cannabidiol is the nonpsychoactive component responsible for marijuana’s antianxiety, antidepressant, antipsychotic, antispastic, anticonvulsant, and antineoplastic properties.
  • THC concentrations in marijuana have risen over the past 20 years from 4% to 12–20% (2).
  • Smoking marijuana results in 25–50% absorption of THC, which rapidly passes into the circulation. The oral bioavailability of THC is much less (3–10%).
  • Effects of smoked marijuana occur within minutes and last several hours; effects from marijuana consumed in foods or beverages appear after 30 minutes to 1 hour and can last up to 4 hours.
  • Frequent users are likely to experience withdrawal.
  • Use in men is reported at 3.5% and women 1.7%; females have a faster transition from recreational use to cannabis use disorder (4).
  • An emerging area of study involved cannabis-related drug interactions and adverse events, which have been noted to be increasing in frequency.
  • Evidence for the use of cannabis to treat pain remains mixed.

Risk Factors

  • Young individuals, especially 18- to 29-year-olds, are at more risk for severe cannabis use disorder (4).
  • Cigarette smokers are at higher risk for cannabis use disorder compared to nonsmokers.
  • Higher potency marijuana increases risk of cannabis use disorder and increases severity of symptoms (5).
  • Family history of chemical dependence
  • Comorbid psychiatric disorders (i.e., antisocial personality disorder)
  • Other substance use (i.e., alcohol, tobacco)
  • Lower educational achievement (rates of dependence are lowest among college graduates)
  • Low socioeconomic status
  • Ease of acquisition of marijuana
  • Among youths with mood disorders, CUD is a risk marker for self-harm, all-cause mortality, and death by unintentional overdose and homicide.

-- To view the remaining sections of this topic, please or --

Basics

Description

  • Marijuana use leading to clinically significant impairment or distress, manifested by two or more of the following symptoms within a 12-month period:
    • Consumption of larger amounts over a longer period of time than intended
    • Persistent desire or inability to cut down or control amount used
    • Inordinate amount of time spent in activities is necessary to obtain, use, or recover from use
    • Presence of craving for cannabis
    • Recurrent use resulting in failure to fulfill major role obligations at work, school, or home
    • Continued use despite having persistent or recurrent social or interpersonal problems due to cannabis use
    • Important social, occupational, or recreational activities are given up or reduced
    • Recurrent use in physically hazardous situations
    • Continued use despite knowledge of a persistent physical or psychological problem caused or exacerbated by cannabis
    • Tolerance defined by using increased amounts of cannabis to achieve the desired effect or intoxication or diminished effect with continued use of the same amount
    • Withdrawal occurs following cessation of prolonged use and has at least three behavioral symptoms such as anxiety, restlessness, depression, irritability, insomnia, odd dreams or physical symptoms such as tremors and/or decreased appetite.
  • According to DSM-5, marijuana or cannabis use disorder is defined as being mild, moderate, or severe depending on how many symptoms are present. Mild: 2 to 3; moderate: 4 to 5; severe: 6+ (1)

Epidemiology

  • The WHO ranks the United States first among 17 European and North American countries for the prevalence of marijuana use.
  • It is estimated that 4.5 to 7 million persons in the United States meet criteria for cannabis use disorder (CUD) annually (2).
  • The prevalence of daily cannabis use in the United States has doubled in the past 2 decades.
  • Cannabis use disorder applies to a subset of marijuana users; ~20% of lifetime marijuana users meet criteria for cannabis use disorder; 23% of these individuals meet criteria for severe use.
  • Risk of CUD is estimated to be 1 in 11 (9%) in adults and 1 in 6 (17%) in adolescents (2).
  • Cannabis is the most widely used illicit psychoactive substance in the United States (22.2 million monthly users) (3).
  • Approximately 30% of students have used marijuana by the time of college entry.
  • In the United States, 10% of marijuana users become daily users, 20–30% become weekly users.
  • In the general population of young people, individuals who use high-potency cannabis are more likely to use cannabis regularly, have cannabis-related problems, use other illicit drugs, and have general anxiety disorder.
  • The landscape is changing rapidly. Many states have legalized marijuana in some form. In 1969, only 12% of people approved of legalizing marijuana; by 2019, 67% approved of legalization.

Etiology and Pathophysiology

  • The two most known therapeutically active cannabinoids in marijuana are δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). While CBD has become much more widely available, it remains prohibited by the FDA.
  • THC is the psychoactive component responsible for marijuana’s analgesic, antiemetic, and intoxicating properties.
  • Cannabidiol is the nonpsychoactive component responsible for marijuana’s antianxiety, antidepressant, antipsychotic, antispastic, anticonvulsant, and antineoplastic properties.
  • THC concentrations in marijuana have risen over the past 20 years from 4% to 12–20% (2).
  • Smoking marijuana results in 25–50% absorption of THC, which rapidly passes into the circulation. The oral bioavailability of THC is much less (3–10%).
  • Effects of smoked marijuana occur within minutes and last several hours; effects from marijuana consumed in foods or beverages appear after 30 minutes to 1 hour and can last up to 4 hours.
  • Frequent users are likely to experience withdrawal.
  • Use in men is reported at 3.5% and women 1.7%; females have a faster transition from recreational use to cannabis use disorder (4).
  • An emerging area of study involved cannabis-related drug interactions and adverse events, which have been noted to be increasing in frequency.
  • Evidence for the use of cannabis to treat pain remains mixed.

Risk Factors

  • Young individuals, especially 18- to 29-year-olds, are at more risk for severe cannabis use disorder (4).
  • Cigarette smokers are at higher risk for cannabis use disorder compared to nonsmokers.
  • Higher potency marijuana increases risk of cannabis use disorder and increases severity of symptoms (5).
  • Family history of chemical dependence
  • Comorbid psychiatric disorders (i.e., antisocial personality disorder)
  • Other substance use (i.e., alcohol, tobacco)
  • Lower educational achievement (rates of dependence are lowest among college graduates)
  • Low socioeconomic status
  • Ease of acquisition of marijuana
  • Among youths with mood disorders, CUD is a risk marker for self-harm, all-cause mortality, and death by unintentional overdose and homicide.

There's more to see -- the rest of this topic is available only to subscribers.